Introduction
Morbidity and mortality due to the quintessential cardiovascular diseases, that is, hypertension and atherosclerosis, leading to stroke and heart failure increase exponentially with advancing age (http://www.cdc.gov/nchs/). The number of Americans over 65 will more than double, from 34.8 million in 2000 (12% of the population) to 70.3 million in 2030 (20% of the total population) [1]. Thus, the incidence and prevalence of arterial diseases will increase dramatically within this time frame.
Age-associated arterial proinflammation is an early molecular manifestation of a chronic stress response, that is, overloading of reactive oxygen species (ROS), of vascular endothelial and smooth muscle cells. This is orchestrated by an age-associated arterial secretory phenotype (AAASP) that involves the concerted effects of numerous angiotensin II (Ang II) biosignaling networks (Table 1) [2 ,3,4 ,5,6 ,7] . Proinflammation fosters a biological 'battlefield' that nurtures arterial diseases (Table 1) [2 ,3,4 ,5,6 ,7] . Arterial dilatation capacity declines after middle age, whereas arterial stiffness becomes markedly increased with aging [5] . Large arterial walls, in particular the intima, remodel with aging. Age-associated changes in cells and matrix magnify susceptibility to macro and micro-environmental insults, rendering the arterial wall a fertile soil in which diseases like hypertension or atherosclerosis flourish.
The review focuses on evidence to support the idea that arterial aging and arterial disease are interwoven at the cellular and molecular levels, namely an AAASP, and that realization of this intertwining of age-disease mechanisms may afford novel approaches to the prevention and treatment of atherosclerosis, hypertension, heart failure, and stroke.
Arterial wall aging
The arterial wall is remodeled by the joint effects of numerous protein alterations, in particular Ang II signaling molecules, with advancing age.
Arterial remodeling
Age-associated arterial remodeling, particularly diffused intimal thickening, is evolutionarily conserved in various species, including rats, rabbits, nonhuman primates, and humans (Table 1) . Thus, findings from experimental arterial aging studies in animals provide insights into the molecular and cellular mechanisms of arterial aging in humans. Age dramatically alters the volume and contents of the arterial intima in rats, nonhuman primates and humans [8,9 ,10-15] . Small disoriented vascular smooth muscle cells (VSMCs), and collagen type I and type III markedly increase within the thickened intima of old rats [8, 12] . Old monkeys ($20 years) have a thickened intima containing cells and matrix beneath an intact endothelium, and nearly all of these cells stain positively for a-smooth muscle actin [10, 16] .
Ang II molecular signaling Molecular elements of the Ang II signaling cascade are upregulated both in aged arterial walls, and play a causal role in arterial aging, and in the diseased vessel (Table 1) . Ang II, angiotensin-converting enzyme (ACE), and the Ang II AT1 receptor are markedly increased with age within the arterial wall, particularly within the thickened intimae in several species, including humans [9 ,10,11] . Interestingly, chymase, another angiotensin convertase, has also been detected in the arterial wall in aged nonhuman and human primates [10, 11] .
Milk fat globule EGF-8 (MFG-E8)
Transcription and translation of arterial milk fat globule EGF-8 (MFG-E8), a novel molecule, is substantially increased with aging in several mammalian species, including humans [6 ] . MFG-E8 expression is stimulated by Ang II and MFG-E8 colocalizes with Ang II and monocyte chemoattractant protein (MCP)-1 within the aged aortic wall [6 ] .
Monocyte chemoattractant protein-1
Transcription, translation, and activity of MCP-1, a powerful chemoattractant and a potential molecular event of intimal hypercellularity is increased within the aged arterial wall [14] . Interestingly, the MCP-1 gradient across the arterial wall from intima to media is substantially increased with aging [11, 14] .
Calpain-1
Ang II induces calpain-1 expression in the aortic wall [9 ] . The transcription, translation, and activity of calpain-1 are significantly upregulated in aortae from old compared with young rats [9 ] .
Transforming growth factor-beta 1
Transforming growth factor-beta1 (TGF-b1) transcription, translation, and activity are increased within the aorta of old compared with young rats [13] . Latent associated protein (LAP)-bound TGF-b1 ($75 kDa) and the latent TGF binding protein-1 (LTBP-1) bound to precursor TGF-b1 (190-250 kDa) also increase within the aged aortic wall, particularly within the thickened intimae [13] .
Matrix metalloproteinase type II Levels of transcription, translation, and activity of matrix metalloproteinase type II (MMP-2) are enhanced within the arterial wall, with aging [8,9 ,10-13,15] . Enhanced arterial wall MMP-2 activity in situ is also observed in several species, including humans [8, [10] [11] [12] [13] . Furthermore, an increase in MMP-2 activity is attributable not only to enhanced transcription and translation, but also to an imbalance of activating and inhibiting factors, for 
example membrane-type 1 matrix metalloproteinase (MT1-MMP) and tissue inhibitor of MMP-2 (TIMP2), respectively [10, 12] .
Reactive oxygen species and nitric oxide bioavailability Arterial NAD(P)H oxidase activation, a major source of ROS, increases with age [2 ,3,17
,18 ,19-21], whereas Cu/Zn superoxide dismutase (SOD), Mg SOD, and extracellular matrix (ECM) SOD decrease in the arterial wall with increasing age [17 ] . This imbalance of oxidase and dismutase consequently results in the increased in-situ superoxide and hydrogen peroxides in the arterial wall with aging [17 ,18 ] .
Reactive oxygen species are major modulators of nitric oxide availability in the aging process [18 ,21] . The decrease in endothelial nitric oxide bioavailability with aging occurs concurrent with an increase in O 2À production, both in the aorta and in the carotid artery [21] . The interaction of nitric oxide and O 2À radicals will result in subsequent formation of peroxynitrite (ONOO À ) [21] . Interventional studies indicate that increased breakdown of nitric oxide due to an augmented production of O 2À is an important key mechanism leading to the decline of endothelium-dependentvasorelaxation withincreasing age [21] .
Arterial aging proteomics
A combined 2D gel and isobaric tag for relative and absolute quantitation (iTRAQ) proteome approach has identified 981 arterial proteins from young and old rats, of which 50 ($5%) were shown to have a significantly different abundance with aging ( 
Specific age-associated effects on vascular cells and matrix
A concurrent remodeling of cells and matrix is the cornerstone of the aging vascular wall.
Endothelial cells
Aging impairs the structure, functions, and regeneration of the endothelium (Fig. 1) , which is tightly controlled by the NF-kB system [17 ] . NF-kB is a key transcription factor that mediates Ang II signaling [17 ] . Recent human studies show that NF-kB p65 is increased in endothelial cells from older patients [19] . Interestingly, the NF-kB inhibitor salsalate efficiently increases expression of the NF-kB inhibitor IkB and reduces NF-kB in endothelial cells, reduces expression of the p47phox nitrotyrosine, and improves brachial artery flow-mediated dilatation in old patients [20] .
Endothelial precursor cells
Aging reduces endothelial precursor cell (EPC) availability and impairs function, including homing, adhesion, spreading, proliferation and migration [22] . Interestingly, the AT1 antagonist valsartan reduces Ang II-accelerated senescence of EPC by upregulation of telomerase activity [23] ; and polyphenol resverotrol inhibits EPC senescence to preserve the integrity of the arterial wall [24] . Furthermore, young rat serum is able to rescue the age-associated decline in the regenerative capability of EPC in vitro and in vivo [25 ] . These findings suggest that a young niche could rescue aged EPC.
Vascular smooth muscle cells
The heterogeneity of the VSMC phenotype substantially increases with aging.
Proliferation
Cultured VSMCs from old rat aortae display accelerated growth rates compared with VSMCs from young rats [26] . Additionally, compared with early passage VSMCs from rat aortae, old VSMCs from young rat aortae have a greater percentage of their population in the S phase, and a lower percentage in the G0/G1 phase [27] . These differences are mediated by dysregulation of the cell cycle, imparted via ERK1/2 signaling that occurs during aging [28] .
Invasiveness
Early passage aortic VSMCs of old rats exhibit an exaggerated chemotactic PDGF-BB response, whereas cells from young aortae require several additional passages in culture to generate an equivalent response [29] . In response to a chemoattractant gradient of PDGE-BB and MCP-1, VSMCs isolated from old aortae also exhibit increased invasion relative to young VSMCs [11, 15] . This age difference is abolished or substantially reduced by losartan, an AT1 atagonist, vCCI, an inhibitor of MCP-1/ CCR2 signaling, GM 6001, an MMP inhibitor, and Ci 1, a calpain inhibitor, or by silencing MFG-E8 [6 ,7,8, 9 ,11,14] . Thus, the increased age-associated VSMC invasion/migration is modulated by concurrent increases in elements of Ang II biosignaling networks.
Senescent proteins
Senescence-associated b-gal activity in the old rat arterial wall is detected in VSMCs enriched with p16 and NOX4 [30, 31 ] . Some aspects of VSMC senescence may be due to telomere shortening (replicative senescence) or to DNA damage response (DDR) to age-associated stress (chronic accumulation of ROS), known as stress-induced premature senescence (SIPS) (Fig. 1) [32,33 -35 ,36] . Telomere shortening and DDR results in the phosphorylation of histones such as H2AX, the association of DNA repair enzymes and cofactors and activation of the transducer protein CHK2 [35 ,36] . These subsequently result in activation of effector molecules such as the breast cancer susceptibility gene BRCA1, E2F transcription factors, p53, p21, and p16 and in inactivation of effector molecules such as Rb and CDK4, and force VSMCs into G1 growth arrest [35 ,36] .
Comparative analysis of the transcriptome profiles of early and late passage human arterial VSMCs found a total of 327 differentially expressed probesets [37 ] . These include interleukin (IL)-1b, IL-8, intercellular adhesion molecule (ICAM)-1, and MCP-1 [37 ] . Furthermore, senescent VSMCs also secrete IL-1, IL-6/8, MCP-1, plasminogen activator inhibitor (PAI)-1, MMP-2 [32, 35 ,36], similar to a phenomenon found in senescent fiobroblasts, referred to as the senescence-associated secretory phenotype (SASP) by Campisi and colleagues [33 ,34 ] . Thus, senescent VSMCs become 'nonconventional' inflammation response (AAASP) cells. Like the SASP, the 204 Pathophysiology of hypertension AAASP also likely allows damaged cells to communicate with the surrounding tissue as providing a complementary signaling role in arterial aging.
Extracellular matrix
Repeated interactions of endothelial cells and VSMCs with ECM via AAASP including Ang II signaling molecules occurs within the arterial wall initiating a journey into subclinical arterial disease. With aging, the ECM becomes fragmented, collagenized, calcified, and glycated ( Fig. 1) [2  ,3 ]. Emerging evidence shows that arterial advanced glycation end products (AGEs) accumulate in arteries with age in rodents, nonhuman primates, and humans [38] [39] [40] . Treatment with alagebrium (formerly named ALT7-111), a thiazolium derivative, can break established AGE cross-links, reversing age-related increases in arterial stiffness in rats, nonhuman primates, and humans [38] [39] [40] .
Links between arterial aging and hypertension
The aging process and essential hypertension cause similar functional and/or structural and molecular modifications (Table 1) . For example, sustained hypertension leads to functional and structural changes of the arterial wall in young patients, similar to normotensive old ones [2 , 41, 42] . These alterations include the endothelialdependent vascular dilatation, pulse wave velocity (PWV), and intimal medial thickness (IMT) [2 , 41, 42] . Further, hypertension accelerates and intensifies ageassociated remodeling of the arterial wall and modifications of its mechanical properties and complications including atherosclerosis, stroke, and heart failure [43] [44] [45] .
Findings from experimental studies with animals provide insights into the molecular and cellular mechanisms of the interaction of aging and hypertension in humans. In-vivo chronic infusion of FXBN rats with Ang II at a subpressor dose increases MMP2 expression and activity, and increases collagen production within the arterial wall [8] ; at higher concentrations sufficient to elicit an increase in arterial pressure of a magnitude similar to that in old rats, there is an increase in MMP2, calpain-1, and TGFb1 activity [8] . Ang II infusion also imparts structural and molecular characteristics of arteries of old, untreated rats to the central arteries of young rats [8, 9 ]. Chronic infusion of phenylephrine, an adrenergic transmitter (a1-AR) known to increase with age [8, 46] , into young rats increases arterial wall Ang II levels, and reproduces Ang II effects [8] . Thus, Ang II signaling can indeed mediate structural, biochemical, and functional features of aging within the arterial wall of young rats and produce hypertension. These results complement those of other studies that have demonstrated that chronic ACE inhibition or AT1 receptor blockade at an early age markedly delays the progression of age-associated arterial remodeling in rodents [47, 48] . In addition, the production of downstream Ang II signaling molecules, TGF-b1 and ROS, and blood pressure increase concomitantly in spontaneously hypertensive rats (SHRs) compared with Wistar-Kyoto (WKY) rats with aging [49] [50] [51] . These findings suggest that Ang II signaling plays a magnified role in the pathogenesis of hypertension disorders with aging, which may reduce lifespan. Indeed, disruption of the Agtr 1a gene that encodes AT1 markedly increases life-span in mice via an enhanced number of mitochondria and upregulation of the prosurvival genes nicotinamide phosphoribosyltransferase and sirtuin 3 [52 ] . Further, lifelong treatment with the AT1 blocker fonsartan in young stroke-prone spontaneously hypertensive rats (SHR-sp) doubles the lifespan to 30 months by alleviating complications of hypertension, compared with the normotensive WKY rats [53] .
Atherosclerosis with aging
The aging process and inflammatory components of prelipid deposition aspects of atherosclerosis cause similar functional and/or structural and molecular modifications (Table 1) . At autopsy, an advanced grade of arterial atherosclerosis is observed in older compared with younger patients [54] . Animal studies show that, although there are similar age alterations in the plasma lipid profile, more prevalent and extensive fatty lesions occur in old mice, rabbit, nonhuman primates than in young ones [55] [56] [57] . Recently, findings from proteomic studies have revealed insights into similar mechanisms involved in arterial aging and atherosclerosis [6 ,58] . In a proteomic analysis of 35 human coronary atherosclerotic plaques that identified a total of 806 proteins [58] , many of the abundant proteins in the atherosclerotic intimae are those that increase in the aged arterial wall (Table 2) , including TGF-b1, periostin, MFG-E8, and PDGF-b [58] , providing additional support for the idea that the aged arterial wall with enhanced Ang II signaling is fertile soil that nurtures atherosclerosis. Further, AT1a deficiency, which effectively protects ApoE À/À mice from the initiation and progression of atherogenesis, exhibits the inhibition of age-associated increases in expression or activation of collagen, 22phox, and MMP-2/9 [59] . Endothelium restricted inhibition of NF-kB activation, achieved by ablation of NEMO/IKKg or by expression of dominant-negative IkBa specifically in endothelial cells, potently reduces atherosclerotic plaque formation in ApoE À/À mice fed with a cholesterol-rich diet with aging [60 ] . The accelerated vascular injury in older LDLR À/À mice is closely associated with the profound inability to mount an antioxidant response [61 ] .
Conclusion
The novel AAASP concept provides an explanation for observation that the arterial wall of younger animals in response to experimental induction of low-grade chronic inflammation, for example by hypertension or early atherosclerosis, is transformed into a phenotype that is strikingly similar to that which develops during aging [2 ,3,62]. Thus, 'aging'-associated arterial changes and those associated with hypertension and atherosclerosis are fundamentally intertwined at the cellular and molecular levels (Table 1) [2 ] . In humans, other well known 'lifestyle' risk factors (e.g. altered lipid metabolism due to dietary indiscretion, smoking, and lack of exercise) likely interact with this arterial substrate that has been altered during aging, rendering the aging artery a fertile soil that facilitates the initiation and magnified progression of arterial diseases [2 ,3] . Lifestyle and pharmacologic interventions have already proved to be effective in preventing or ameliorating vascular disease associated with aging [2 ,3] . The subclinical AAASP affords novel targets to reduce the incidence and progression of the quintessential age-associated arterial diseases, that is hypertension and atherosclerosis.
